Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price ...

Bayer upgraded to Buy at Goldman Sachs, saying risk/reward into H2 2025 looks positive and catalysts including upcoming ...

Investing.com -- Shares of Bayer AG (ETR: BAYGN) were up over 5% on Thursday after Goldman Sachs upgraded the German pharmaceutical and life sciences company to a "buy" rating from "neutral ...

On Thursday, Goldman Sachs analysts upgraded Bayer AG (ETR:BAYGN) (BAYN:GR) (OTC: BAYRY) stock from Neutral to Buy. The new price target is set at €33.00, up from the previous €29.10.

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The word on The Street in general, suggests a Hold analyst consensus rating for Bayer with a €26.69 average price target, which is a 18.91% upside from current levels. In a report released on ...

Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year. BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month ...